NCT03921294View on ClinicalTrials.gov

HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

PHASE4TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

March 16, 2022

Study Completion Date

March 16, 2022

Conditions

Haemophilic Pseudotumour

Interventions

DRUG

Emicizumab

bispecific monoclonal antibody binding to activated Factor IX and Factor X

Trial Locations (1)

46260

Indiana Hemophila @Thrombosis Center, Indianapolis

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Indiana Hemophilia &Thrombosis Center, Inc.

OTHER